Clinical trial
An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate Its Safety in Indian Participants With Relapsed and Refractory Multiple Myeloma Who Have Previously Received at Least 3 Prior Lines of Therapy Including an Immunomodulatory Agent, a Proteasome Inhibitor and an Anti-CD38 Antibody and Have Demonstrated Disease Progression on the Last Therapy
NCT07030517 is registered in ClinicalTrials.gov with Johnson & Johnson Private Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate Its Safety in Indian Participants With Relapsed and Refractory Multiple Myeloma Who Have Previously Received at Least 3 Prior Lines of Therapy Including an Immunomodulatory Agent, a Proteasome Inhibitor and an Anti-CD38 Antibody and Have Demonstrated Disease Progression on the Last Therapy
- Lead sponsor
- Johnson & Johnson Private Limited
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- May 22, 2025
- Completion date
- February 14, 2027
- Enrollment
- 75 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.